Is There a Benefit of Combining Immunotherapy and Radiotherapy in Bladder Cancer?

Area of Science:

• Oncology
• Immunology
• Radiotherapy

Background:

• Metastatic urothelial cancer (mUC) treatment has been revolutionized by immune checkpoint inhibitors (ICIs).
• However, only a minority of mUC patients respond to anti-programmed death ligand-1 (anti-PD-1) monotherapy.
• Radiotherapy (RT) exhibits local and systemic anti-tumor effects via immune modulation.

Purpose of the Study:

• To review preclinical and clinical evidence for combining RT with immunotherapy in urothelial cancer.
• To explore the potential of this combination to enhance anti-tumor immune responses and improve patient outcomes.
• To suggest future research directions in this field.

Main Methods:

• Systematic review of preclinical studies investigating RT/immunotherapy interactions.
• Analysis of early-phase clinical trials combining RT and ICIs in urothelial cancer.
• Synthesis of evidence regarding immune modulation by RT and its synergy with ICIs.

Main Results:

• Preclinical data suggest RT can enhance ICI efficacy through immune system modulation.
• Early clinical trials show promise for RT/ICI combinations in urothelial cancer.
• The combination strategy warrants further investigation to optimize treatment protocols.

Conclusions:

• Combining radiotherapy with immune checkpoint inhibitors holds significant potential for treating urothelial cancer.
• Further research and clinical trials are needed to establish optimal strategies and confirm efficacy.
• This approach may overcome resistance to anti-PD-1 monotherapy and improve survival rates.